Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients
Authors
Keywords
-
Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 356, Issue -, Pages 577599
Publisher
Elsevier BV
Online
2021-05-04
DOI
10.1016/j.jneuroim.2021.577599
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rituximab for the treatment of multiple sclerosis: a review
- (2021) Clara Grazia Chisari et al. JOURNAL OF NEUROLOGY
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: implication for vaccination program?
- (2021) Stefano Gelibter et al. Multiple Sclerosis and Related Disorders
- Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab
- (2021) Ramon E Flores-Gonzalez et al. Multiple Sclerosis and Related Disorders
- Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis
- (2021) Nicola Capasso et al. Multiple Sclerosis and Related Disorders
- Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
- (2020) Hui Wang et al. CELL
- Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination
- (2020) Crystal Zheng et al. CNS DRUGS
- Immune-mediated neurological syndromes in SARS-CoV-2-infected patients
- (2020) Antoine Guilmot et al. JOURNAL OF NEUROLOGY
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient
- (2020) Hannah Wurm et al. Multiple Sclerosis Journal
- Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study
- (2020) Amit Bar-Or et al. NEUROLOGY
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide
- (2020) Luca Bollo et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
- (2020) Shengli Xia et al. LANCET INFECTIOUS DISEASES
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
- (2020) Evan J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- (2020) Cheryl Keech et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
- (2020) David Baker et al. Multiple Sclerosis and Related Disorders
- COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
- (2020) Virginia Meca-Lallana et al. Multiple Sclerosis and Related Disorders
- Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia
- (2020) William L Conte Multiple Sclerosis and Related Disorders
- Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
- (2020) Matteo Lucchini et al. Multiple Sclerosis and Related Disorders
- Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
- (2020) Jeanine Rempe Thornton et al. Multiple Sclerosis and Related Disorders
- Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
- (2020) Marcello De Angelis et al. Multiple Sclerosis and Related Disorders
- Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study
- (2020) Lindsey R Baden et al. Lancet HIV
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
- (2020) Katie J. Ewer et al. NATURE MEDICINE
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intradermal SynCon® Ebola GP DNA Vaccine is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers
- (2019) Pablo Tebas et al. JOURNAL OF INFECTIOUS DISEASES
- Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
- (2019) Kayvon Modjarrad et al. LANCET INFECTIOUS DISEASES
- Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis
- (2019) Mauricio F. Farez et al. NEUROLOGY
- Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy
- (2018) H. K. Olberg et al. EUROPEAN JOURNAL OF NEUROLOGY
- mRNA vaccines — a new era in vaccinology
- (2018) Norbert Pardi et al. NATURE REVIEWS DRUG DISCOVERY
- Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder
- (2018) Maureen A. Mealy et al. Multiple Sclerosis and Related Disorders
- Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies
- (2018) Christoph Metze et al. CNS Neuroscience & Therapeutics
- Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
- (2018) Stefan Gingele et al. Cells
- Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design
- (2017) Timothy Pepini et al. JOURNAL OF IMMUNOLOGY
- Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response
- (2017) Darin K. Edwards et al. Journal of Translational Medicine
- Cladribine to Treat Relapsing Forms of Multiple Sclerosis
- (2017) Gavin Giovannoni Neurotherapeutics
- Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine — Preliminary Report
- (2017) Pablo Tebas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disease activity return after natalizumab cessation in multiple sclerosis
- (2016) Maria Rasenack et al. Expert Review of Neurotherapeutics
- Disease activity return after natalizumab cessation in multiple sclerosis
- (2016) Maria Rasenack et al. Expert Review of Neurotherapeutics
- Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment
- (2016) Stacy Ellen Hatcher et al. JAMA Neurology
- Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease
- (2015) Darren M. Roberts et al. JOURNAL OF AUTOIMMUNITY
- Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
- (2014) Arumugam Palanichamy et al. JOURNAL OF IMMUNOLOGY
- Established and novel disease-modifying treatments in multiple sclerosis
- (2014) A. H. Cross et al. JOURNAL OF INTERNAL MEDICINE
- Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis
- (2014) Michael Kaufman et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study
- (2014) Henning K Olberg et al. Multiple Sclerosis Journal
- Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies
- (2014) Paolo Pellegrino et al. VACCINE
- The effect of rituximab on vaccine responses in patients with immune thrombocytopenia
- (2013) I. Nazi et al. BLOOD
- Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis
- (2013) A. Bar-Or et al. NEUROLOGY
- Immune competence after alemtuzumab treatment of multiple sclerosis
- (2013) C. L. McCarthy et al. NEUROLOGY
- Humoral immune response to influenza vaccine in natalizumab-treated MS patients
- (2012) Mattias Vågberg et al. NEUROLOGICAL RESEARCH
- Humoral-Targeted Immunotherapies in Multiple Sclerosis
- (2012) Sabeen Lulu et al. Neurotherapeutics
- Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment
- (2011) O. E. Yri et al. BLOOD
- The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis
- (2011) Bernd C. Kieseier CNS DRUGS
- Glatiramer Acetate in the Treatment of Multiple Sclerosis
- (2011) Patrice H. Lalive et al. CNS DRUGS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started